Peptides DB
Research-centric peptide and protocol reference hub

Thymosin Beta-4 (Tβ4) record · updated 20h ago

Healing & recoveryInflammation & immuneGrade A · human clinicalResearch use only
All 6 studiesJump to the evidenceCompare
What is Thymosin Beta-4 (Tβ4) used for?

Thymosin Beta-4 (Tβ4) is a 43-amino acid peptide that plays a significant role in tissue repair and regeneration. It is involved in various biological processes, including cell migration, angiogenesis, and inflammation modulation. Tβ4 has been shown to promote wound healing by enhancing keratinocyte migration and proliferation, as well as by facilitating the formation of new blood vessels, which are crucial for tissue repair.

How it works: Actin-sequestering peptide; promotes cell migration & angiogenesis

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection (research use)

Development stage

where Thymosin Beta-4 (Tβ4) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 18 registered trials. It describes the research record, not a recommendation.

Identity
NameThymosin Beta-4 (Tβ4)
Chain length43 amino acids
Molecular weight4,963 Da
FormulaC212H350N56O78S
Structure typePeptide
ClassHealing
Research levelModerate Research
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 45382195. The chain length is only shown where the residues account for that mass, so a figure here has been checked against it rather than taken on trust.

Pharmacology
MechanismActin-sequestering peptide; promotes cell migration & angiogenesis
RouteSubcutaneous injection (research use)
Half-life—
Time to peak—
Duration—
Extraction confidence0.50
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 15, 2026. How this works →
Research stats
Total studies6
Human / animal / cellular2 / 1 / 1
Highest trial phasePhase 3
Years covered2010–2026
Latest study11d ago
Publication history
20102026
Research funding
5 NIH projects · $1.9M awarded · through FY2023
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

6 rowsOpen in the library →
StudyTypeYearSummary depth
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
FindingNot reported in abstract.
review2026Full text read0.80
[Risk factors of death in patients with bloodstream infections in a medical intensive care unit].
FindingLYM≤0.5×10^9/L at bloodstream infection onset had an odds ratio (OR) of 3.268, 95%CI 1.196-8.927, P=0.021.
Human2026Full text read0.80
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
TakeawayNot reported in abstract.
—2025Title only0.20
Identification of Thymosin β4 as an effector of Hand1-mediated vascular development.
FindingNot reported in abstract.
Animal2010Full text read0.70
[Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic study in vitro].
FindingNot reported in abstract.
In vitro2026Full text read0.70
Thymosin Beta 4 as an Early Biomarker in Sepsis Induced Acute Kidney Injury
FindingNot reported in abstract.
Human2021Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Thymosin Beta-4 (Tβ4) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Thymosin Beta-4 (Tβ4) is discussed should be drawn from it.